Background Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of
its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune …

Background Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T
cells, can overcome immune resistance. We assessed the antitumor activity and safety of …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …

Background Nivolumab has shown improved survival in the treatment of advanced non-small-cell
lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety …

Background Phase 3 clinical data has shown higher proportions of patients with objective
response, longer response duration, and longer overall survival with nivolumab versus …

There is growing attention from governments and regulators towards crucial matters such as
climate change and global warming, resulting in a pressing need to investigate the factors …

Background Immuno-oncology (IO) therapies target the host immune system, providing the
potential to choose a uniform dose and schedule across tumor types. However, dose …

BACKGROUND: To determine the potential efficacy of targeting both the tumor and bone
microenvironment in patients with castration‐resistant prostate cancer (PC), the authors …

Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and
recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies …

BACKGROUND: The recently developed the Src and Abelson (Abl) kinase inhibitor
dasatinib has antitumor effects in epithelial and mesenchymal tumors. Preclinical data have …